Literature DB >> 1900398

Desflurane is a trigger of malignant hyperthermia in susceptible swine.

D J Wedel1, P A Iaizzo, J H Milde.   

Abstract

Desflurane (difluoromethyl 1-fluoro 2,2,2-trifluoroethyl ether: CF2-H-O-CFH-CF3) is a potent inhalation anesthetic agent being investigated for possible clinical use. The authors examined the effects of this agent on normal swine and those from a special breeding program that were considered purebred for susceptibility to malignant hyperthermia (MH). Animals were exposed to 1 or 2 MAC or both doses of desflurane and observed for changes in end-tidal CO2, arterial blood gases, lactate, catecholamines, core temperature, blood pressure, and heart rate. All normal swine tolerated exposure to desflurane without clinical signs of MH, but significant changes in heart rate and blood pressure were noted. In contrast, of six MH susceptible swine tested, two had unequivocal MH reactions to deflurane, defined by significant increases of end-tidal CO2 (greater than 50 mmHg), an increase in PaCO2 (greater than 70 mmHg), a decrease in blood pH (less than 7.30), an increase in blood lactate concentration, and an increase in core temperature. Two other susceptible swine showed equivocal signs of MH but not until desflurane had been administered for 40-60 min. Finally, two other susceptible swine showed no signs of MH after 60 min of exposure to 2 MAC desflurane. These latter four animals all developed episodes of MH immediately after intravenous succinylcholine (2 mg/kg). The increased PaCO2, blood lactate concentrations, and temperature, and the decrease in pH induced by desflurane, were successfully treated with dantrolene and supportive measures. All surviving animals were biopsied 1 to 2 weeks after the exposure to desflurane for in vitro contracture testing to confirm MH susceptibility.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900398     DOI: 10.1097/00000542-199103000-00020

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

Review 1.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

2.  Malignant hyperthermia involving the administration of desflurane.

Authors:  E S Fu; J E Scharf; D Mangar; W D Miller
Journal:  Can J Anaesth       Date:  1996-07       Impact factor: 5.063

Review 3.  Desflurane. A review of its pharmacodynamic and pharmacokinetic properties and its efficacy in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 4.  Desflurane clinical pharmacokinetics and pharmacodynamics.

Authors:  J E Caldwell
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

Review 5.  In vitro contractile studies within isolated tissue baths: Translational research from Visible Heart® Laboratories.

Authors:  Weston J Upchurch; Paul A Iaizzo
Journal:  Exp Biol Med (Maywood)       Date:  2022-01-22

Review 6.  The clinical use of desflurane.

Authors:  E I Eger
Journal:  Yale J Biol Med       Date:  1993 Sep-Oct
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.